S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Assembly Biosciences Stock Forecast, Price & News

+0.09 (+4.29%)
(As of 07/1/2022 03:59 PM ET)
Today's Range
50-Day Range
52-Week Range
14,308 shs
Average Volume
510,160 shs
Market Capitalization
$105.59 million
P/E Ratio
Dividend Yield
Price Target

Assembly Biosciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
272.1% Upside
$8.15 Price Target
Short Interest
4.92% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.17mentions of Assembly Biosciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$7,995 Sold Last Quarter
Proj. Earnings Growth
From ($2.13) to ($1.69) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.14 out of 5 stars

Medical Sector

330th out of 1,427 stocks

Pharmaceutical Preparations Industry

155th out of 680 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ASMB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Assembly Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Assembly Biosciences logo

About Assembly Biosciences (NASDAQ:ASMB) Stock

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

ASMB Stock News Headlines

27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Assembly Row names seven new tenants
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Assembly Biosciences Inc - Stock Chart
Assembly Biosciences GAAP EPS of -$0.48
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$6.25 million
Book Value
$3.53 per share


Free Float
Market Cap
$105.59 million

Social Links

Assembly Biosciences Frequently Asked Questions

Should I buy or sell Assembly Biosciences stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Assembly Biosciences stock.
View analyst ratings for Assembly Biosciences
or view top-rated stocks.

What is Assembly Biosciences' stock price forecast for 2022?

4 equities research analysts have issued 12-month price targets for Assembly Biosciences' stock. Their ASMB stock forecasts range from $3.10 to $14.00. On average, they anticipate Assembly Biosciences' share price to reach $8.15 in the next year. This suggests a possible upside of 272.1% from the stock's current price.
View analysts' price targets for Assembly Biosciences
or view top-rated stocks among Wall Street analysts.

How has Assembly Biosciences' stock price performed in 2022?

Assembly Biosciences' stock was trading at $2.33 at the start of the year. Since then, ASMB stock has decreased by 6.0% and is now trading at $2.19.
View the best growth stocks for 2022 here

When is Assembly Biosciences' next earnings date?

Assembly Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Assembly Biosciences

How were Assembly Biosciences' earnings last quarter?

Assembly Biosciences, Inc. (NASDAQ:ASMB) posted its earnings results on Thursday, May, 12th. The biopharmaceutical company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.01.
View Assembly Biosciences' earnings history

Who are Assembly Biosciences' key executives?

Assembly Biosciences' management team includes the following people:
  • Dr. John G. McHutchison A.O., FRACP, M.D., CEO, Pres & Director (Age 64, Pay $1.47M) (LinkedIn Profile)
  • Mr. Jason A. Okazaki, Chief Operating Officer (Age 46, Pay $841.32k)
  • Dr. William E. Delaney IV, Ph.D., Chief Scientific Officer (Age 50, Pay $637.9k)
  • Dr. Uri A. Lopatin M.D., Co-Founder and Clinical & Scientific Advisor (Age 50)
  • Dr. Adam Zlotnick, Co-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory Board
  • Mr. Michael P. Samar, CFO & Principal Accounting Officer (Age 49)
  • Ms. Jennifer A. Troia MHROD, SHRM-SCP, SPHR, Chief HR Officer
  • Dr. Richard J. Colonno, Sr. Advisor (Age 72)
  • Dr. Tharaknath Rao, Head of Microbiome Clinical Devel. & Sr. VP
  • Dr. Luisa M. Stamm M.D., Ph.D., Chief Medical Officer (Age 46)

What is John McHutchison's approval rating as Assembly Biosciences' CEO?

5 employees have rated Assembly Biosciences CEO John McHutchison on Glassdoor.com. John McHutchison has an approval rating of 80% among Assembly Biosciences' employees.

What other stocks do shareholders of Assembly Biosciences own?

What is Assembly Biosciences' stock symbol?

Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB."

How do I buy shares of Assembly Biosciences?

Shares of ASMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Assembly Biosciences' stock price today?

One share of ASMB stock can currently be purchased for approximately $2.19.

How much money does Assembly Biosciences make?

Assembly Biosciences (NASDAQ:ASMB) has a market capitalization of $105.59 million and generates $6.25 million in revenue each year. The biopharmaceutical company earns $-129,850,000.00 in net income (profit) each year or ($2.81) on an earnings per share basis.

How many employees does Assembly Biosciences have?

Assembly Biosciences employs 102 workers across the globe.

When was Assembly Biosciences founded?

Assembly Biosciences was founded in 2005.

How can I contact Assembly Biosciences?

Assembly Biosciences' mailing address is 331 OYSTER POINT BOULEVARD FOURTH FLOOR, SOUTH SAN FRANCISCO CA, 94080. The official website for Assembly Biosciences is www.assemblybio.com. The biopharmaceutical company can be reached via phone at (833) 509-4583, via email at lglaser@assemblybio.com, or via fax at 646-706-5101.

This page (NASDAQ:ASMB) was last updated on 7/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.